These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 12070410)
1. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Ramdani A; Mignon M; Samoyeau R Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410 [TBL] [Abstract][Full Text] [Related]
2. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936 [TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with Zollinger-Ellison syndrome. Mignon M; Pospai D; Forestier S; Vatier J; Vallot T Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592 [TBL] [Abstract][Full Text] [Related]
4. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045 [TBL] [Abstract][Full Text] [Related]
5. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461 [TBL] [Abstract][Full Text] [Related]
6. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Miner P; Katz PO; Chen Y; Sostek M Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806 [TBL] [Abstract][Full Text] [Related]
7. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094 [TBL] [Abstract][Full Text] [Related]
8. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. Welage LS; Berardi RR J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250 [TBL] [Abstract][Full Text] [Related]
10. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Lew EA; Pisegna JR; Starr JA; Soffer EF; Forsmark C; Modlin IM; Walsh JH; Beg M; Bochenek W; Metz DC Gastroenterology; 2000 Apr; 118(4):696-704. PubMed ID: 10734021 [TBL] [Abstract][Full Text] [Related]
11. [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal]. Paul G; Ramdani A; Mignon M; Vallot T; Forestier S; Cadiot G; Ruszniewski P; Joubert-Collin M Gastroenterol Clin Biol; 1994; 18(8-9):695-701. PubMed ID: 7875436 [TBL] [Abstract][Full Text] [Related]
12. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Metz DC; Comer GM; Soffer E; Forsmark CE; Cryer B; Chey W; Pisegna JR Aliment Pharmacol Ther; 2006 Feb; 23(3):437-44. PubMed ID: 16423003 [TBL] [Abstract][Full Text] [Related]
13. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Metz DC Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353 [TBL] [Abstract][Full Text] [Related]
14. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Hirschowitz BI; Simmons J; Mohnen J Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694 [TBL] [Abstract][Full Text] [Related]
15. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Cheer SM; Prakash A; Faulds D; Lamb HM Drugs; 2003; 63(1):101-33. PubMed ID: 12487624 [TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753 [TBL] [Abstract][Full Text] [Related]
18. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632 [TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Hirschowitz BI; Mohnen J; Shaw S Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754 [TBL] [Abstract][Full Text] [Related]
20. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Désir B; Poitras P Can J Gastroenterol; 2001 Dec; 15(12):795-8. PubMed ID: 11773945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]